Table 1 Demographic, clinical and substance use in virally suppressed people living with HIV, QuAliV -ANRS CO3 AQUIVIH-NA Cohort, 2018–2019, Nouvelle-Aquitaine, France) (N = 660)
Statistics* | |||
|---|---|---|---|
Demographics | |||
Age (mean, s.d.) | 54.7 ± 11.2 | ||
Sex (% male) | 487 (72.4) | ||
Country of birth (% born in France) | 561 (85.0) | ||
HIV infection | |||
Time since diagnosis (years) (mean, s.d.) | 20.0 ± 9.7 | ||
HIV transmission risk group | |||
Men who have sex with men | 318 (48.2) | ||
IV drug use | 70 (10.6) | ||
Heterosexual contact | 229 (34.7) | ||
Other | 43 (6.5) | ||
Last CD4 count (cells/mm3) | 736.4 ± 333.8 | ||
Last CD8 count (cells/mm3) | 775.1 ± 387.5 | ||
Last CD4/CD8 ratio | 1.1 ± 0.6 | ||
1.0 [0.0–5.7] | |||
< 1 | 315 (47.7) | ||
≥ 1 | 345 (52.3) | ||
Drug use | |||
Tobacco | |||
Current smoker | 225 (34.5) | Very low to low nicotine addiction1 | 52 (31.3) |
Medium nicotine addiction1 | 55 (33.1) | ||
Strong nicotine addiction1 | 37 (22.3) | ||
Very strong nicotine addiction1 | 22 (13.3) | ||
Former smoker | 225 (34.5) | ||
Never smoker | 202 (31.0) | ||
Alcohol | |||
Current drinker | 539 (82.8) | No misuse2 | 307 (61.0) |
Hazardous drinking2 | 185 (36.8) | ||
Alcohol use disorder2 | 11 (2.2) | ||
Non-drinker | 112 (17.2) | ||
Cannabis | |||
Current user (last 12 months) | 129 (19.9) | ||
Non-user | 519 (80.1) | ||
Other drugs | |||
Current user (last 12 months) | 76 (11.9) | ||
Non-user | 563 (88.1) | ||
Use in a private home | |||
Poppers | 63 (82.9) | 53 (84.1) | |
Cocaine | 26 (34.2) | 24 (92.3) | |
Amphetamines/ecstasy/MDMA/methamphetamines | 21 (27.6) | 9 (42.9) | |
Synthetic cathinones | 38 (50.0) | 37 (97.4) | |
GHB GBL | 19 (25.0) | 18 (94.7) | |
Opiates | 3 (3.9) | 3 (100.0) | |
Synthetic cannabinoids | 0 (0.0) | - | |
“Chemsex drug user”** | 69 (90.8) |